The proportions of immunocompromised patients (7.55% vs. 4.43%; p = 0.007), central intravenous catheter use (7.05% vs. 4.43%; p = 0.022), history of beta-lactam/beta-lactamase inhibitor use (8.91% vs. 5.86%; p = 0.018), infections by extended-spectrum beta-lactamase (ESBL)-producing Gram-negative bacteria (4.33% vs. 1.20%; p < 0.001), and infections by carbapenem-resistant Enterobacterales (1.36% vs. 0.36%; p = 0.032) were significantly higher during the pre-implementation period compared with during the post-implementation period. This evidence concerns the gene LACTB and infection.